| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/02/2023 | 37.66% | Morgan Stanley | $318 → $314 | Maintains | Overweight |
| 11/02/2023 | 35.03% | Wedbush | $307 → $308 | Maintains | Outperform |
| 08/03/2023 | 39.41% | Morgan Stanley | $316 → $318 | Maintains | Overweight |
| 08/03/2023 | 17.49% | Ladenburg Thalmann | $256 → $268 | Maintains | Buy |
| 08/03/2023 | 34.59% | Wedbush | $305 → $307 | Maintains | Outperform |
| 08/03/2023 | 31.52% | HC Wainwright & Co. | → $300 | Reiterates | Buy → Buy |
| 05/04/2023 | 12.23% | Ladenburg Thalmann | $285 → $256 | Maintains | Buy |
| 04/21/2023 | 22.75% | Argus Research | $300 → $280 | Maintains | Buy |
| 04/10/2023 | 35.91% | UBS | $330 → $310 | Maintains | Buy |
| 04/10/2023 | 38.54% | Morgan Stanley | $320 → $316 | Maintains | Overweight |
| 02/23/2023 | 22.75% | JP Morgan | $265 → $280 | Maintains | Overweight |
| 02/23/2023 | 40.29% | Morgan Stanley | $330 → $320 | Maintains | Overweight |
| 02/23/2023 | 31.52% | HC Wainwright & Co. | → $300 | Reiterates | → Buy |
| 01/11/2023 | 31.52% | Argus Research | $250 → $300 | Maintains | Buy |
| 12/06/2022 | 44.67% | Morgan Stanley | $322 → $330 | Maintains | Overweight |
| 12/06/2022 | 40.29% | UBS | → $320 | Initiates Coverage On | → Buy |
| 12/05/2022 | 0.83% | Goldman Sachs | → $230 | Initiates Coverage On | → Sell |
| 11/03/2022 | 16.18% | JP Morgan | $240 → $265 | Maintains | Overweight |
| 11/03/2022 | 41.17% | Morgan Stanley | $288 → $322 | Maintains | Overweight |
| 11/03/2022 | 64.4% | Oppenheimer | $325 → $375 | Maintains | Outperform |
| 11/03/2022 | 31.52% | HC Wainwright & Co. | $255 → $300 | Maintains | Buy |
| 10/11/2022 | 26.26% | Morgan Stanley | → $288 | Initiates Coverage On | → Overweight |
| 05/24/2022 | 4.34% | JP Morgan | $225 → $238 | Maintains | Overweight |
| 05/24/2022 | 7.41% | Jefferies | $223 → $245 | Maintains | Buy |
| 05/24/2022 | 15.3% | Wedbush | $236 → $263 | Maintains | Outperform |
| 05/24/2022 | 8.29% | Credit Suisse | $219 → $247 | Maintains | Outperform |
| 05/24/2022 | 11.79% | HC Wainwright & Co. | $248 → $255 | Maintains | Buy |
| 04/19/2022 | -2.24% | JP Morgan | $230 → $223 | Maintains | Overweight |
| 02/28/2022 | 3.46% | Wedbush | $276 → $236 | Maintains | Outperform |
| 02/25/2022 | -11% | Ladenburg Thalmann | $231 → $203 | Maintains | Buy |
| 02/11/2022 | — | BTIG | Initiates Coverage On | → Neutral | |
| 07/14/2021 | -10.13% | Argus Research | → $205 | Upgrades | Hold → Buy |
| 05/06/2021 | 8.72% | HC Wainwright & Co. | $195 → $248 | Maintains | Buy |
| 04/08/2021 | -7.06% | JP Morgan | $185 → $212 | Maintains | Overweight |
| 02/22/2021 | -14.07% | Credit Suisse | $169 → $196 | Maintains | Outperform |
| 02/16/2021 | 20.56% | Oppenheimer | $200 → $275 | Maintains | Outperform |
| 02/01/2021 | -14.51% | HC Wainwright & Co. | $125 → $195 | Upgrades | Neutral → Buy |
| 07/30/2020 | -27.66% | Oppenheimer | $155 → $165 | Maintains | Outperform |
| 07/30/2020 | 6.97% | Wedbush | $243 → $244 | Maintains | Outperform |
| 06/25/2020 | -36.43% | Credit Suisse | $129 → $145 | Maintains | Outperform |
| 06/25/2020 | -45.2% | HC Wainwright & Co. | $85 → $125 | Maintains | Neutral |
| 03/10/2020 | -46.08% | Jefferies | $115 → $123 | Upgrades | Hold → Buy |
| 02/27/2020 | -36.43% | Cowen & Co. | $119 → $145 | Upgrades | Market Perform → Outperform |
| 02/13/2020 | -46.95% | Credit Suisse | $113 → $121 | Maintains | Outperform |
| 01/31/2020 | -47.39% | JP Morgan | $116 → $120 | Upgrades | Neutral → Overweight |
| 08/01/2019 | -53.53% | Ladenburg Thalmann | $103 → $106 | Upgrades | Neutral → Buy |
| 08/01/2019 | -60.54% | Jefferies | → $90 | Upgrades | Underperform → Hold |
| 07/01/2019 | — | Credit Suisse | Upgrades | Neutral → Outperform | |
| 05/17/2019 | -58.79% | UBS | $115 → $94 | Upgrades | Sell → Neutral |
| 05/09/2019 | — | Credit Suisse | Upgrades | Underperform → Neutral | |
| 05/02/2019 | 19.68% | Wedbush | $269 → $273 | Maintains | Outperform |
| 03/01/2019 | -58.35% | Barclays | $100 → $95 | Maintains | Underweight |
| 11/19/2018 | -53.97% | Credit Suisse | $103 → $105 | Maintains | Underperform |
What is the target price for United Therapeutics (UTHR)?
The latest price target for United Therapeutics (NASDAQ: UTHR) was reported by Morgan Stanley on November 2, 2023. The analyst firm set a price target for $314.00 expecting UTHR to rise to within 12 months (a possible 37.66% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for United Therapeutics (UTHR)?
The latest analyst rating for United Therapeutics (NASDAQ: UTHR) was provided by Morgan Stanley, and United Therapeutics maintained their overweight rating.
When is the next analyst rating going to be posted or updated for United Therapeutics (UTHR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United Therapeutics was filed on November 2, 2023 so you should expect the next rating to be made available sometime around November 2, 2024.
Is the Analyst Rating United Therapeutics (UTHR) correct?
While ratings are subjective and will change, the latest United Therapeutics (UTHR) rating was a maintained with a price target of $318.00 to $314.00. The current price United Therapeutics (UTHR) is trading at is $228.10, which is out of the analyst's predicted range.